… in individuals recovering from predominantly mild infections (p=0.004), which was further
accompanied by lower proportions of several Treg subsets compared to controls (p<0.006). …

The combination of the anti-PD-L1 antibody atezolizumab and the anti-VEGF bevacizumab
is the first approved immunotherapeutic regimen for first-line therapy in patients with …

The pandemic coronavirus disease 2019 (COVID-19) can cause multi-systemic symptoms
that can persist beyond the acute symptomatic phase. The post-acute sequelae of COVID-19 (…

… At the time of scanning groups differed significantly with respect to depressive symptoms
measured by MADRS (p < 0.001, Cohens d = 1.46) and cognitive symptoms measured by …

… Results with p < 0.05 in two-sided tests were considered … [p = 0.062] or supermarkets as
‘neutral’ [p = 0.65] and they ‘disagreed’ with being afraid of being infected in hospitals [p = 0.03]. …

The severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has prompted search
for therapeutics tackling both the pathogen and the overwhelming host response, on an …

… We present nominal two-sided p values. For the analyses, we used SPSS 26 (IBM Inc, … In
addition, p values from comparing post-COVID patients with MSC patients are provided above …

… All tests were 2-sided, and p values of less than 0.05 were considered to indicate
statistical significance. Analyses were performed with R software version 3.5.3 (R foundation). …

… Multiplicity adjustment followed O'Brien, 21 with nominal significance levels of p = 0.005
at interim analysis and p = 0.048 at final analysis. All patients enrolled up to this point were …

… Overall, 71.4% of the IBD patients and 85.2% of the controls showed levels of anti-SARS-CoV-2
antibodies above the cutoff of 33.8 BAU/ml [p = 0.329] after the first dose. Even in the …